04.09.18
Lesaffre Human Care, a supplier of ingredients from yeast and bacteria fermentation for the global human care markets, has had two new studies published related to its S. cerevisiae-based ingredients in preventing vaginal infections and helping women manage their day-to-day intimate health. The studies were published in the Medical Journal of Obstetrics and Gynecology and in Beneficial Microbes.
“As an ingredient supplier, we believe that obtaining such scientific validation is paramount; which is why we are committed to standing out among ingredients suppliers by delivering second to none expert information to our customers and acting an industry-leader in this regard. We pledge to always provide safe ingredients vetted by the scientific community and that offer unique benefits backed by extensive research. In doing so, we seek to bring extra value to the health & nutrition industry while building trust and lasting relationships with our partners,” explained Véronique Lhommet, Women’s Health Product Manager at Lesaffre Human Care.
To further their knowledge of S. cerevisiae CNCM I-3856 benefits on women’s intimate health, the company launched a clinical study. The goal was to research the effects of oral administration of this probiotic yeast as an adjuvant therapy in women suffering from vulvovaginal candidiasis (VVC). Results, which spearheaded the publication in the Medical Journal of Obstetrics and Gynecology of one of the new scientific papers, showed that probiotic yeast S. cerevisiae CNCM I-3856 is “easy-to-use and well tolerated” and that “the probiotic yeast is efficient in controlling vaginal Candida proliferation after conventional treatment thus limiting VVC recurrence.”
“Writers also called our exclusiveS. cerevisiae-based probiotic a “natural breakthrough for vaginal health,” which is invaluable for over 75% of women around the world who experience at least one episode of vaginal infection in their life, many of whom suffering from recurrence,” explained Ms. Lhommet.
In addition to these findings, the peer-reviewed paper published in Beneficial Microbes revealed promising anti-fungal and anti-inflammatory properties for vaginal candidiasis therapy. Researchers concluded that “the beneficial effect exerted by thisS. cerevisiae-based probiotic is the result of its interference with the expression of fungus virulence factors coupled with the modulation of the inflammatory response of the host.”
All of these new discoveries strengthen previous research results on Lesaffre Human Care’s S. cerevisiae-based ingredients for women health enhancement and prompt the company to keep investing in clinical research to reveal the full potential of each and every one of its health-promoting ingredients.
“As an ingredient supplier, we believe that obtaining such scientific validation is paramount; which is why we are committed to standing out among ingredients suppliers by delivering second to none expert information to our customers and acting an industry-leader in this regard. We pledge to always provide safe ingredients vetted by the scientific community and that offer unique benefits backed by extensive research. In doing so, we seek to bring extra value to the health & nutrition industry while building trust and lasting relationships with our partners,” explained Véronique Lhommet, Women’s Health Product Manager at Lesaffre Human Care.
To further their knowledge of S. cerevisiae CNCM I-3856 benefits on women’s intimate health, the company launched a clinical study. The goal was to research the effects of oral administration of this probiotic yeast as an adjuvant therapy in women suffering from vulvovaginal candidiasis (VVC). Results, which spearheaded the publication in the Medical Journal of Obstetrics and Gynecology of one of the new scientific papers, showed that probiotic yeast S. cerevisiae CNCM I-3856 is “easy-to-use and well tolerated” and that “the probiotic yeast is efficient in controlling vaginal Candida proliferation after conventional treatment thus limiting VVC recurrence.”
“Writers also called our exclusiveS. cerevisiae-based probiotic a “natural breakthrough for vaginal health,” which is invaluable for over 75% of women around the world who experience at least one episode of vaginal infection in their life, many of whom suffering from recurrence,” explained Ms. Lhommet.
In addition to these findings, the peer-reviewed paper published in Beneficial Microbes revealed promising anti-fungal and anti-inflammatory properties for vaginal candidiasis therapy. Researchers concluded that “the beneficial effect exerted by thisS. cerevisiae-based probiotic is the result of its interference with the expression of fungus virulence factors coupled with the modulation of the inflammatory response of the host.”
All of these new discoveries strengthen previous research results on Lesaffre Human Care’s S. cerevisiae-based ingredients for women health enhancement and prompt the company to keep investing in clinical research to reveal the full potential of each and every one of its health-promoting ingredients.
